Table 1 Evolution of laboratory parameters and discontinuation of therapy
Parameter (Reference or limit of detection) | Day after onset of illness | |||||
|---|---|---|---|---|---|---|
8 | 9 | 12 | 21 | 40 | 75 | |
AST (<40 U/l) | 1920 | 1787 | 578 | 53 | 31 | 26 |
ALT(<55 U/l) | 1743 | 1650 | 1021 | 122 | 27 | 25 |
yGT(<35 U/l) | 265 | 226 | 221 | 102 | 35 | 20 |
ALP (42–98 U/l) | 352 | 296 | 302 | 150 | 70 | 58 |
Bilirubin (<20 umol/l) | 15 | 15 | 13 | 16 | ||
CRP(<5 mg/l) | 41 | 35 | 14 | 37 | 12 | 4 |
CMV IgG (neg) | Neg | |||||
CMV IgM (neg) | Neg | |||||
Hepatitis A IgM (neg) | Neg | |||||
HBs Antigen (neg) | Neg | |||||
HBc Ig (neg) | Pos | Neg | ||||
HBc IgM (neg) | Pos | Neg | ||||
HBe Ig (neg) | Neg | Neg | ||||
HBe Antigen (neg) | Neg | |||||
HBs Ig (neg) | Neg | |||||
HBV DNA (<9 IU/ml) | <9 | |||||
Hepatitis C Ig (neg) | Neg | |||||
EBV VCA IgG (neg) | Pos | |||||
EBV NA1 IgG (neg) | Pos | |||||
EBV VCA IgM (neg) | Pos | Pos | ||||
EBV DNA (<122 IU/ml) | 566 | <122 | <122 | |||
Heterophile IM (neg) | Neg | |||||
HEV IgG (neg); Diapro | Pos | |||||
HEV IgM (neg); Diapro | Pos | |||||
HEV IgG (<1.0 index); Wantai | 5.3 | 19.4 | 19.5 | |||
HEV IgM (<1.0 index); Wantai | 10.4 | 10.6 | 10.6 | |||
HEV RNA (<1000 cc/ml) | 8959 | <1000 | <1000 | |||
Stop (\) and reinitiation (/) of | ||||||
- Prednisolon therapy | 8 \ | / 48 | ||||
- Methotrexate therapy | 8 \ | / 63 | ||||